Randomized, Multicenter, Two-Arm, Open-Label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif New Formulation From Rebif (Interferon Beta-1a) [subcutaneously injected, 44mcg three-times-weekly] With Ibuprofen PRN [when necessary] or as Prophylaxis.

Trial Profile

Randomized, Multicenter, Two-Arm, Open-Label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif New Formulation From Rebif (Interferon Beta-1a) [subcutaneously injected, 44mcg three-times-weekly] With Ibuprofen PRN [when necessary] or as Prophylaxis.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Interferon beta-1a (Primary) ; Ibuprofen
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRANSFER
  • Sponsors EMD Serono; Merck KGaA; Merck Serono
  • Most Recent Events

    • 13 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 20 Sep 2008 Primary endpoint results presented at ECTRIMS/ACTRIMS/LACTRIMS
    • 29 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top